Want to see CH:PPGN full AI Analyst Report?
PPGN Stock Chart & Stats
CHF43.95
CHF0.05(0.11%)
At close: 4:00 PM EDT
CHF43.95
CHF0.05(0.11%)
Day’s Range― - ―
52-Week RangeCHF21.80 - CHF50.10
Previous CloseN/A
Volume526.45K
Average Volume (3M)34.07K
Market Cap
CHF1.45B
Enterprise ValueCHF1.63K
Total Cash (Recent Filing)CHF59.21M
Total Debt (Recent Filing)CHF139.52M
Price to Earnings (P/E)109.2
Beta1.24
Next Earnings
Mar 09, 2027EPS Estimate
0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.43
Shares Outstanding33,125,000
10 Day Avg. Volume33,840
30 Day Avg. Volume34,067
Financial Highlights & Ratios
PEG Ratio-5.17
Price to Book (P/B)2.72
Price to Sales (P/S)2.36
P/FCF Ratio-30.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF44.10Price Target Upside0.35% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)0.87
Revenue Forecast (FY)CHF496.39M
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained top-line growth indicates continued demand for PolyPeptide’s peptide and oligonucleotide CDMO services. Expanding customer programs and commercial manufacturing volumes can support capacity utilization and provide a foundation for longer-term operating recovery.
Improving Operating Cash FlowPositive and improving operating cash flow shows that core operations are generating funding despite reported net losses. This supports ongoing development and manufacturing activity, reduces reliance on external financing, and strengthens resilience through the recovery period.
Specialized CDMO PlatformPolyPeptide combines process development, analytical, quality, regulatory, and cGMP manufacturing services in specialized molecules. This integrated expertise can deepen customer relationships and create switching costs as programs progress from clinical development to commercial supply.
Bears Say
Persistent Net LossesOngoing net losses indicate that the business has not yet converted revenue growth into sustainable shareholder returns. Continued losses can limit internal reinvestment, weaken equity, and increase dependence on operational improvement or external capital.
Margin CompressionThe sharp decline from earlier profitability suggests pressure from cost inflation, underutilized capacity, execution issues, or unfavorable project mix. Margin recovery may require stronger utilization and pricing discipline, making earnings improvement uncertain over the medium term.
Volatile Free Cash FlowNegative and inconsistent free cash flow indicates that investment and working-capital requirements can absorb operating cash generation. This may constrain financial flexibility, particularly while the company remains loss-making and continues expanding or upgrading capacity.
PolyPeptide Group AG News
PPGN FAQ
What was PolyPeptide Group AG’s price range in the past 12 months?
PolyPeptide Group AG lowest stock price was CHF21.80 and its highest was CHF50.10 in the past 12 months.
What is PolyPeptide Group AG’s market cap?
PolyPeptide Group AG’s market cap is CHF1.45B.
When is PolyPeptide Group AG’s upcoming earnings report date?
PolyPeptide Group AG’s upcoming earnings report date is Mar 09, 2027 which is in 190 days.
How were PolyPeptide Group AG’s earnings last quarter?
PolyPeptide Group AG released its earnings results on Aug 13, 2026. The company reported CHF0.252 earnings per share for the quarter, beating the consensus estimate of CHF0.065 by CHF0.187.
Is PolyPeptide Group AG overvalued?
According to Wall Street analysts PolyPeptide Group AG’s price is currently Undervalued.
Does PolyPeptide Group AG pay dividends?
PolyPeptide Group AG pays a Notavailable dividend of CHF0.3 which represents an annual dividend yield of N/A. See more information on PolyPeptide Group AG dividends here
What is PolyPeptide Group AG’s EPS estimate?
PolyPeptide Group AG’s EPS estimate is 0.57.
How many shares outstanding does PolyPeptide Group AG have?
PolyPeptide Group AG has 33,125,000 shares outstanding.
What happened to PolyPeptide Group AG’s price movement after its last earnings report?
PolyPeptide Group AG reported an EPS of CHF0.252 in its last earnings report, beating expectations of CHF0.065. Following the earnings report the stock price went up 0.114%.
Which hedge fund is a major shareholder of PolyPeptide Group AG?
Currently, no hedge funds are holding shares in CH:PPGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PolyPeptide Group AG
PolyPeptide Group AG operates globally as a contract development and manufacturing organization (CDMO), specializing in the production of Good Manufacturing Practice (GMP)-grade peptides. These peptides, available in both proprietary and generic forms, are vital for pharmaceutical and biotechnology companies, serving as key ingredients in approved medicines, compounds undergoing clinical development, and generic drug formulations. The company also produces custom research-grade peptides and actively develops neoantigen peptides to support personalized cancer therapies. Its manufacturing expertise extends to peptides used in commercially approved therapeutics, peptide-based generics for human and veterinary applications, and cosmetic peptides. Additionally, PolyPeptide Group AG provides regulatory affairs support services. Founded in 1952 and headquartered in Zug, Switzerland, the company is a subsidiary of Draupnir Holding B.V.
PPGN Stock 12 Month Forecast
Average Price Target
CHF44.10
▲(0.35% Upside)
Technical Analysis
Lonza Group Ltd
―
Bachem Holding AG
―
Siegfried Holding AG
―
Sandoz Group Ltd
―
Joincare Pharmaceutical Group Industry Co., Ltd. Sponsored GDR Class A RegS
―